Biological
Shingrix clinical trials
Also written Shingrix and Herpes Zoster Vaccine GSK1437173A.
- studies test it
- 59
- open now
- 14
- in phase 3
- 24
- first study started
- 2009
Keep track of what changes. Save the shingrix studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
59 studies that test it; most in 2023 (10)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2010 | 4 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 5 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 8 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 6 |
| 2023 | 10 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 7
- Phase 2
- 11
- Phase 3
- 24
- Phase 4
- 15
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 33 · Other 26
GlaxoSmithKline (28) · University of Colorado, Denver (4) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Region Skane (2) · Dynavax Technologies Corporation (1) · Tor Biering-Sørensen (1) · Suzhou Abogen Biosciences Co., Ltd. (1) · University of Washington (1)
Often tested with
Tested in the same studies.
Chickenpox Vaccine (2) · Z-1018 (1) · ABO1108 (1) · Arexvy (1) · MVA-BN smallpox vaccine (1) · Escherichia coli lipopolysaccharide (1) · Candida albicans Antigen Injection (1) · Adenovirus Vector (1)
Studies
Open first, then newest update. How each study uses shingrix is read from its arms, and is right about nine times in ten.
Testing it · 59
- A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk FactorsNot yet recruitingPhase 3GlaxoSmithKlineNCT07872046Written as RZV vaccine
- Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control PopulationRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT05580458Written as Shingrix
- Shingrix In Recipients of Allogeneic TransplantsRecruitingPhase 2University of Colorado, DenverNCT05775718Written as Zoster Vaccine Recombinant
- VZV in the Enteric Nervous System: Pathogenesis and ConsequencesRecruitingPhase 4Vanderbilt University Medical CenterNCT05550194Written as Shingrix
- Vaccine Responses in Patients With B Cell MalignanciesRecruitingPhase 4National Heart, Lung, and Blood Institute (NHLBI)NCT05170399Written as Shingrix
- A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in FinlandRecruitingPhase 4GlaxoSmithKlineNCT07502560Written as Recombinant zoster vaccine
- Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant RecipientsRecruitingNot applicableCentral Adelaide Local Health Network IncorporatedNCT06262776Written as Recombinant zoster vaccine adjuvanted (SHINGRIX)
- Shingrix in Renal Transplant RecipientsRecruitingPhase 3University of Colorado, DenverNCT04128189Written as Shingrix
- Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant RecipientsEnrolling by invitationPhase 4Ann & Robert H Lurie Children's Hospital of ChicagoNCT06162494Written as Recombinant Zoster Vaccine
- Safety of the Herpes Zoster Subunit Vaccine in LupusRecruitingPhase 4NYU Langone HealthNCT05559671Written as Herpes Zoster Subunit (HZ/su) Vaccine
- Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic DiseasesEnrolling by invitationPhase 4Region SkaneNCT06763783Written as Shingrix
- Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis PatientsRecruitingPhase 4Prof Patrice LaliveNCT05596526Written as recombinant zoster vaccine
- Immunogenicity, Reactogenicity of Shingrix in SLERecruitingPhase 3Seoul National University HospitalNCT06001606Written as Shingrix
- Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant RecipientsRecruitingPhase 2Loyola UniversityNCT05554068Written as Shingrix
- Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and OverActive, not recruitingPhase 1/2Dynavax Technologies CorporationNCT06569823Written as Shingrix
- Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and DementiaActive, not recruitingPhase 4Tor Biering-SørensenNCT07485283Written as Recombinant Herpes Zoster Vaccine (Shingrix)
- Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCTWithdrawnPhase 4Tuen Mun HospitalNCT04748939Written as recombinant subunit herpes zoster vaccine
- Phase I Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or AboveActive, not recruitingPhase 1Suzhou Abogen Biosciences Co., Ltd.NCT07285265Written as SHINGRIX
- The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using AbataceptCompletedPhase 2Kevin WinthropNCT03604406Written as Varicella Zoster Vaccine
- VZV-specific Tissue Resident Memory T-cells After Shingrix VaccinationActive, not recruitingPhase 4University of WashingtonNCT04403139Written as Shingrix
See all 59 studies that test shingrix →
Given in every arm · 4 — shingrix is usual care beside what is tested
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic DiseasesActive, not recruitingPhase 4University of Sao Paulo General HospitalNCT05879419Written as Recombinant Herpes Zoster Vaccine (RZV)
- A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in AdultsCompletedPhase 3PfizerNCT06890416Written as HZ/su VACCINE
- Simultaneous RZV and aIIV4 VaccinationCompletedPhase 4Duke UniversityNCT05007041Written as SHINGRIX®
- A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster VaccineCompletedPhase 3GlaxoSmithKlineNCT05047770Written as HZ/su
As the comparator · 17 — what is tested is compared with shingrix
- Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and AboveNot yet recruitingPhase 2Aribio Lab Co., Ltd.NCT07481604Written as Shingrix
- A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy IndividualsRecruitingPhase 1/2Shanghai Institute Of Biological ProductsNCT06932523Written as Shingrix (GSK)
- A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy ParticipantsNot yet recruitingPhase 2Shenzhen Shenxin Biotechnology Co., LtdNCT07205796Written as Shingrix
- Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and OlderRecruitingPhase 1Guangzhou Patronus Biotech Co., Ltd.NCT06874842Written as Positive control
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster VaccineNot yet recruitingPhase 1/2Sinocelltech Ltd.NCT06801509Written as Shingrix®
- Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and AboveRecruitingPhase 1CHA Vaccine Institute Co., Ltd.NCT06137755Written as Shingrix
- Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and AboveCompletedPhase 2MAXVAX Biotechnology Limited Liability CompanyNCT05856084Written as Positive control
- Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and AboveCompletedPhase 1MAXVAX Biotechnology Limited Liability CompanyNCT05636436Written as Positive control
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of AgeTerminatedPhase 1ModernaTX, Inc.NCT05701800Written as Shingrix
- A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy AdultsTerminatedPhase 1/2PfizerNCT05703607Written as Shingrix
- A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster VaccineActive, not recruitingPhase 2Immorna Biotherapeutics, Inc.NCT06581575Written as Shingrix
- A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy ParticipantsCompletedPhase 1Shenzhen Shenxin Biotechnology Co., LtdNCT06375512Written as Shingrix
- Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and OlderActive, not recruitingPhase 2Curevo IncNCT05304351Written as Shingrix
- Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 YearsActive, not recruitingPhase 1EuBiologics Co.,LtdNCT06409494Written as Shingrix
- A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 YearsActive, not recruitingPhase 1Guangzhou Patronus Biotech Co., Ltd.NCT06335849Written as SHINGRIX
- The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell)CompletedPhase 1Jiangsu Rec-Biotechnology Co., Ltd.NCT05769049Written as Shingrix
- Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult VolunteersCompletedPhase 1Dynavax Technologies CorporationNCT05245838Written as Shingrix
Codes
What other systems call shingrix · ClinicalTrials.gg INT002157
- MeSH (NLM) C000731890shingrixOne source NLM
- UNII (FDA) COB9FF6I46RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGENConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731890 | shingrix | One source NLM |
| UNII (FDA) | COB9FF6I46 | RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.